Упатство за практикување на медицина заснована на докази при хронична опструктивна белодробна болест (ХОББ)

Objectives

This clinical guideline establishes an evidence-based framework for the diagnosis, treatment and long-term management of chronic obstructive pulmonary disease (COPD), requiring healthcare professionals and health associates to provide care in accordance with its recommendations.[1]Its scope covers diagnostic principles, disease definitions and causes, symptoms and signs, patient communication, pharmacological and non-pharmacological therapy, home inhaled treatment, acute exacerbations, domiciliary oxygen and referral.[2]

• Improve recognition and diagnosis of COPD through assessment of persistent respiratory symptoms, smoking history, clinical examination and spirometry.[2][3][4]
• Distinguish COPD from asthma and assess airflow limitation, using bronchodilator testing and objective lung-function measures where appropriate.[2][4]
• Relieve symptoms and tailor treatment intensity to symptom severity, lung-function impairment and individual response to therapy.[5]
• Address smoking as the principal associated risk factor and support smoking cessation as part of COPD management.[2][3]
• Manage acute exacerbations promptly while limiting antibiotics and theophylline to clinically indicated circumstances.[6][7]
• Prevent exacerbations and support long-term health through pulmonary rehabilitation, regular exercise, influenza vaccination and recommended pneumococcal vaccination.[7]
• Provide long-term oxygen therapy for appropriately assessed patients with severe chronic hypoxaemia, with the intended aim of improving quality of life and preventing or delaying pulmonary hypertension.[8][9]

The guideline presents a clinical rather than a broader health-system strategy. It does not specify population-level prevention targets, national implementation objectives, budgets or a wider respiratory-health mission beyond the management of COPD.[1][2]

Implementation

Care is delivered through assessment-led, stepped clinical management that combines inhaled treatment, rehabilitation, vaccination, exacerbation care and, for selected patients, home oxygen, surgery, non-invasive ventilation or supported home care.[5][7][10][11][12]The recommendations emphasise treatment selection according to clinical response, objective findings and patient suitability rather than a uniform regimen.[5][13]

• Assess patients through history-taking, auscultation and recognition of cough with sputum, progressive dyspnoea and respiratory infections; use spirometry as the primary diagnostic basis, while recognising the limited diagnostic role of chest radiography.[3][4]
• Use short-acting inhaled anticholinergics or beta-2 agonists for symptom relief, and consider long-acting bronchodilators or combinations where sustained symptom control is required.[13]
• Consider inhaled corticosteroids for selected patients with an objective benefit or frequent exacerbations, while recognising their limited effect on lung function.[13]
• Reserve aminophylline or theophylline for selected or exceptional cases, account for medicine interactions and adverse effects, and monitor serum concentrations when necessary or feasible.[13][6]
• Use controlled oxygen, preferably by Venturi mask or nasal catheter, during acute exacerbations and avoid excessive oxygen concentrations or flow in relevant patient groups.[6]
• Add inhaled short-acting sympathomimetic bronchodilators, potentially with ipratropium bromide, and consider systemic corticosteroids during exacerbations.[6]
• Consider antibiotics when worsening dyspnoea, sputum volume and sputum purulence indicate a likely infective exacerbation.[7]
• Provide pulmonary rehabilitation, exercise support and immunisation as continuing components of long-term care.[7]
• Assess eligibility for domiciliary oxygen critically, including stable severe hypoxaemia, capacity to cooperate and the expectation that oxygen will improve arterial oxygen pressure without worsening carbon-dioxide retention.[9]
• Deliver home oxygen mainly through concentrators, use cylinders where electricity is unavailable and consider liquid oxygen for mobile patients.[10]
• Support continuous oxygen treatment through cooperation between patients and the clinical team, including rehabilitation-instructor home visits for patients using oxygen at home.[10]
• Consider non-invasive ventilation during acute exacerbations to reduce mortality and intubation, and use supported home care with specialised nursing as an alternative to hospital care for selected patients.[11][12]
• Refer selected patients for thorough evaluation before bullectomy, lung transplantation or lung-volume-reduction surgery.[5]

Implementation accountability rests principally with treating healthcare professionals and health associates.[1]A doctor may depart from the guideline only in exceptional individual cases, provided that the reasons, necessity and subsequent treatment plan are documented in the patient’s medical record.[1]The supplied material does not specify implementation timelines, formal governance structures, workforce training, institutional reporting or a system-wide monitoring framework.[1][14][15]

Monitoring & Evaluation

No document-wide monitoring, evaluation, surveillance, performance-indicator, reporting or institutional accountability framework is specified in the supplied material.[1][2][3][9][10][12][14][15][16]Monitoring is instead embedded in clinical decision-making, treatment response, safety assessment and follow-up for selected interventions.[4][5][13][6][8]

• Document any exceptional departure from the guideline in the patient’s medical record, including the reasons, clinical need and subsequent treatment plan.[1]
• Assess diagnosis and bronchodilator response through spirometry, including peak expiratory flow and forced expiratory volume in one second; a response of more than 15% following 400 micrograms of salbutamol is described as objective evidence of bronchodilator responsiveness.[4]
• Continue inhaled corticosteroid treatment where an objective response is present, while recognising that the source describes limited effects on lung function.[4][13]
• Base treatment selection on symptom severity, impaired lung function and clinical response, and undertake thorough objective assessment before considering surgical treatment.[5]
• Monitor serum theophylline concentrations when necessary or where possible, particularly when treatment is used after inadequate response to other therapies.[13][6]
• Assess arrhythmias and convulsions as potential indicators of theophylline toxicity, and consider adverse effects and medicine interactions when using theophylline.[13]
• Review domiciliary oxygen therapy through critical assessment and appropriate follow-up, with the responsible clinical team supporting decisions to initiate or continue treatment.[8]
• Use home visits by a rehabilitation instructor to assess patients receiving continuous oxygen therapy at home and support ongoing cooperation between patients and the treatment team.[10]
• Apply evidence grades, ranging from A to C, to distinguish interventions supported by stronger evidence from those with weaker or uncertain evidence, including triple therapy, home oxygen, inhaler-device selection and nutritional interventions.[11]

The material provides clinical measures that may inform individual patient review, including spirometry, blood-gas analysis in advanced disease, assessment of respiratory symptoms and examination findings.[3][4]It does not define aggregate targets, data-collection systems, reporting frequency, responsible oversight institutions, audit processes, sanctions, public accountability mechanisms or evaluation schedules.[1][2][12][14][15][16]

Costing & Financing

No costs, budgets, financing sources, funding allocations, resource-mobilisation mechanisms, funding gaps or economic assumptions are specified in the supplied material.[1][2][3][4][9][10][11][12][14][15][16][17]The guidance identifies service inputs and treatment modalities, but does not attach financial values or describe how they are to be funded.[6][7][8][10][11]

• Identify oxygen concentrators, oxygen cylinders where electricity is unavailable, and liquid oxygen for mobile patients as delivery options for home oxygen therapy, without specifying procurement, maintenance or patient costs.[10]
• Identify rehabilitation-instructor home visits and specialised nursing support for selected patients as service-delivery inputs, without specifying staffing budgets or reimbursement arrangements.[10][12]
• Identify pulmonary rehabilitation, exercise, vaccination, bronchodilators, corticosteroids, antibiotics, non-invasive ventilation and oxygen therapy as clinical interventions, without specifying their resource requirements or affordability assumptions.[6][7][8][11]
• Provide no cost-effectiveness analysis, financial prioritisation criteria, household-cost assessment, insurance arrangements or estimate of resources needed to implement the recommendations.[9][10][11][12]